APLS Q2 2018 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$2B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$33M

Operating Income

-$33M

Net Income

-$33M

EPS (Diluted)

$-0.61

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$267M

Total Liabilities

$37M

Stockholders' Equity

$230M

Cash & Equivalents

$254M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$33M	$0	—
Operating Income	-$33M	-$12M	-176.0%
Net Income	-$33M	-$12M	-174.9%